RegCell
10 known investors
RegCell Biosciences is a biotechnology company developing regenerative cell therapies, leveraging expertise in cell and gene therapy, manufacturing, and immunology to advance therapeutic treatments.
Founders & leadership
MM
Michael McCullar, PhDChief Executive Officer
JA
James AhlersChief Financial Officer
MG
Marty Giedlin, PhDChief Technology Officer
TH
Tony HurleyChief Technical Operations Officer
SK
Steve Kanner, PhDChief Scientific Officer
Investors · 10
Fast Track InitiativeTokyo · $1.2M – $184M
Global BrainTokyo · $100K – $184M
Kyoto University Innovation CapitalKyoto
UTECTokyo · $3.1M – $78M
Mitsubishi UFJ CapitalreportedTokyo · $952K – $269M
Also in the syndicate · 5
Celadon PartnersFast Track Initiative (FTI)leadKyoto University Innovation Capital (Kyoto i-Cap)Osaka University Venture Capital (OUVC)The University of Tokyo Edge Capital Partners (UTEC)lead
Funding
SEC filings, press & company announcements$45M disclosed across 1 of 2 rounds · 2025
- Undisclosed amountseed roundMar 2025
Fast Track Initiative (FTI) (lead), The University of Tokyo Edge Capital Partners (UTEC) (lead), Celadon Partners, Kyoto University Innovation Capital (Kyoto i-Cap), Mitsubishi UFJ Capital, Osaka University Venture Capital (OUVC)
Source ↗ - $45MraisedMar 2025 · 4 sources
Fast Track Initiative (FTI) (lead)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 3
by search overlapRegeneron NASDAQ: REGN www.regeneron.com5 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Read on Scientific American4 shared keywordsScientific American is a science and technology news publication covering research, discoveries, and developments across fields such as astronomy, biology, physics, health, and climate. It publishes articles, magazine issues, discussions, and organizes reader travel experiences and editorial features.
Lyell4 shared keywordsLyell is a clinical-stage biotech developing next-generation CAR T-cell product candidates intended as one-time treatments for patients with cancer, targeting both hematologic malignancies and solid tumors. The company owns and operates its own manufacturing facility to control its cell therapy supply chain.
Companies competing with RegCell for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does RegCell do?
- RegCell Biosciences is a biotechnology company developing regenerative cell therapies, leveraging expertise in cell and gene therapy, manufacturing, and immunology to advance therapeutic treatments.
- Who are RegCell's investors?
- RegCell's investors include Fast Track Initiative, Global Brain, Kyoto University Innovation Capital, UTEC, Mitsubishi UFJ Capital.
- How much funding has RegCell raised?
- RegCell has disclosed $45M raised across 1 of its 2 known rounds.